Ginkgo bioworks announces strategic purchase of epidemiological data infrastructure assets

Transaction is expected to bolster ginkgo's growing biosecurity platform and provide expanded epidemic tracking, modeling, and forecasting offerings to public health leaders and communities boston , aug. 19, 2022 /prnewswire/ -- ginkgo bioworks (nyse: dna), the leading horizontal platform for cell programming, today announced the purchase of certain epidemiological data infrastructure assets from baktus, inc., a delaware-based public benefit corporation. under the terms of the deal, ginkgo will assume ownership of proprietary datasets, modeling and analytic tools, and a software platform with the capabilities to track, model, and forecast epidemics and associated risks and impacts.
DNA Ratings Summary
DNA Quant Ranking